<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04476043</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 54707-204</org_study_id>
    <nct_id>NCT04476043</nct_id>
  </id_info>
  <brief_title>To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of INCB054707 in participants with hidradenitis
      suppurativa over a 16-week placebo-controlled treatment period followed by a 36 -week
      open-label extension period.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 31, 2020</start_date>
  <completion_date type="Anticipated">September 26, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Triple</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in total AN count</measure>
    <time_frame>Week 16</time_frame>
    <description>Defined as mean change of Abscess and Inflammatory Nodule (AN) count relative to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who achieve HiSCR</measure>
    <time_frame>Week 16</time_frame>
    <description>HiSCR defined as at least a 50% decrease from baseline in AN count with no increase in the number of abscesses or draining fistulas.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who achieve HiSCR at each visit</measure>
    <time_frame>Weeks 2 to 12</time_frame>
    <description>HiSCR defined as at least a 50% decrease from baseline in AN count with no increase in the number of abscesses or draining fistulas.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who achieve HSCR75 at each visit</measure>
    <time_frame>Weeks 2 to 16</time_frame>
    <description>HiSCR75 defined as at least a 75% decrease from baseline in AN count with no increase in the number of abscesses or draining fistulas.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in IHS4 at each visit</measure>
    <time_frame>Weeks 2 to 16</time_frame>
    <description>Defined as change from baseline in the International Hidradenitis Suppurativa Severity Score System (IHS4).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving AN50, AN75, AN90, and AN100 at each visit</measure>
    <time_frame>Weeks 2 to 16</time_frame>
    <description>Defined as reduction in AN count by at least 50%, 75%, 90% and 100% relative to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in AN count relative to baseline at each visit</measure>
    <time_frame>Weeks 2 to 12</time_frame>
    <description>Defined as mean change of Abscess and Inflammatory Nodule (AN) count relative to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving AN of 0 to 2 at each visit</measure>
    <time_frame>Weeks 2 to 16</time_frame>
    <description>Defined as Abscess and Inflammatory Nodule (AN) count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in the draining fistula count at each visit</measure>
    <time_frame>Weeks 2 to 16</time_frame>
    <description>Defined as the mean change from baseline in the draining fistulas count at each visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in ANF count at each visit</measure>
    <time_frame>Weeks 2 to 16</time_frame>
    <description>Defined as the mean change from baseline in the sum of abscess, inflammatory nodule, and draining fistula count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>56 weeks</time_frame>
    <description>A TEAE is any adverse event (AE) either reported for the first time or worsening of a pre-existing event after first dose of study drug.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hidradenitis Suppurativa</condition>
  <condition>Acne Inversa</condition>
  <arm_group>
    <arm_group_label>INCB054707 Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive INCB054707 Dose A for 16 weeks (Period 1) followed by INCB054707 Dose C for 36 weeks (Period 2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INCB054707 Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive INCB054707 Dose B for 16 weeks (Period 1) followed by INCB054707 Dose C for 36 weeks (Period 2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INCB054707 Dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive INCB054707 Dose C for 52 weeks (Period 1 + Period 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo followed by INCB054707 Dose C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo for 16 weeks (Period 1) followed by INCB054707 Dose C for 36 weeks (Period 2).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB054707</intervention_name>
    <description>Oral; Tablet</description>
    <arm_group_label>INCB054707 Dose A</arm_group_label>
    <arm_group_label>INCB054707 Dose B</arm_group_label>
    <arm_group_label>INCB054707 Dose C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral; Tablet</description>
    <arm_group_label>Placebo followed by INCB054707 Dose C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HS disease duration of at least 3 months before screening.

          -  Willingness to avoid pregnancy or fathering children.

          -  Active HS in at least 2 distinct anatomical areas.

          -  Participants agree NOT to use topical antiseptics on the areas affected by HS lesions
             during the placebo-controlled 16-week treatment period

        Exclusion Criteria:

          -  Draining fistula count of &gt; 20 at screening or baseline.

          -  Women who are pregnant (or who are considering pregnancy) or lactating.

          -  Medical history including thrombocytopenia, coagulopathy or platelet dysfunction,
             Q-wave interval abnormalities, current or history of certain infections, cancer,
             lymphoproliferative disorders and other medical conditions at the discretion of the
             investigator.

          -  History of failure to treatment of inflammatory diseases with JAK inhibitors.

          -  Have evidence of active or latent or inadequately treated infection with Mycobacterium
             tuberculosis.

          -  Participants known to be infected with HIV, Hepatitis B, or Hepatitis C.

          -  Laboratory values outside of the protocol-defined ranges.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Incyte Corporation Call Center (US)</last_name>
    <phone>1.855.463.3463</phone>
    <email>medinfo@incyte.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Incyte Corporation Call Center (ex-US)</last_name>
    <phone>+800 00027423</phone>
    <email>eumedinfo@incyte.com</email>
  </overall_contact_backup>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 15, 2020</study_first_submitted>
  <study_first_submitted_qc>July 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2020</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hidradenitis Suppurativa</mesh_term>
    <mesh_term>Hidradenitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.</ipd_time_frame>
    <ipd_access_criteria>Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://www.incyte.com/our-company/compliance-and-transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

